KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Equity Income (2019 - 2022)

Biogen (BIIB) has 8 years of Equity Income data on record, last reported at $45.0 million in Q2 2022.

  • For Q2 2022, Equity Income changed 0.0% year-over-year to $45.0 million; the TTM value through Mar 2023 reached $45.0 million, down 65.83%, while the annual FY2022 figure was $2.6 million, 92.55% down from the prior year.
  • Equity Income reached $45.0 million in Q2 2022 per BIIB's latest filing, up from -$3.3 million in the prior quarter.
  • Across five years, Equity Income topped out at $45.0 million in Q2 2021 and bottomed at -$140.9 million in Q4 2019.
  • Average Equity Income over 4 years is -$2.0 million, with a median of -$8.2 million recorded in 2020.
  • The widest YoY moves for Equity Income: up 443.51% in 2021, down 8.33% in 2021.
  • A 4-year view of Equity Income shows it stood at -$140.9 million in 2019, then soared by 112.78% to $18.0 million in 2020, then skyrocketed by 150.0% to $45.0 million in 2021, then changed by 0.0% to $45.0 million in 2022.
  • Per Business Quant database, its latest 3 readings for Equity Income were $45.0 million in Q2 2022, -$3.3 million in Q1 2022, and $45.0 million in Q4 2021.